Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.

Stryker (NYSE:SYK) recently received FDA clearance for its Incompass® Total Ankle System, a significant product innovation that highlights the company's commitment to advancing patient care. Over the ...

We recently published a list of 11 Best Medical Device Stocks to Buy Now. In this article, we are going to take a look at where Stryker Corporation (NYSE:SYK) stands against other best medical ...

In a report released today, Travis Steed from Bank of America Securities maintained a Buy rating on Stryker (SYK – Research Report), with a price target of $450.00. The companys ...

Looking at stock returns, SYK, with 0% returns in the last twelve months, has fared better than ISRG stock, down 20%, and the broader S&P500 index, down 9%.

SYK has a three-year EPS compound annual growth rate (CAGR) of 18.01% and revenue CAGR of 9.60%, respectively. With that SYK seems promising, ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Investors in Stryker Corp (Symbol: SYK) saw new options begin trading today, for the September 2026 expiration. One of the key data points that goes into the price an option buyer is willing to ...

Investors in Stryker Corp (Symbol: SYK) saw new options become available today, for the February 2025 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SYK ...